Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rosell

Showing results (201-210 of 265) with videos related to

Pageof 27
Sort By:
Oncogene|January 7, 1998
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosisJ M de Anta, E Jassem, R Rosell, et al.
Psychopharmacology|May 1, 2014
Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112Judy L Thompson, Daniel R Rosell, Mark Slifstein, et al.
Schizophrenia Research|April 12, 2024
The MATRICS consensus cognitive battery for the assessment of cognitive impairment in schizotypal personality disorderKatelyn N Challman, Daniel R Rosell, Deanna Barch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancerD Isla, R Rosell, J J Sánchez, et al.
The American Journal of Psychiatry|January 19, 2019
Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality DisorderMargaret M McClure, Fiona Graff, Joseph Triebwasser, et al.
British Journal of Cancer|March 26, 2008
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimenJ Wei, Z Zou, X Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1997
Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancerM Sánchez-Céspedes, R Rosell, A Pifarré, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2000
Altered HOX and WNT7A expression in human lung cancerR Calvo, J West, W Franklin, et al.
British Journal of Cancer|May 10, 2014
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancerJ Wei, C Costa, J Shen, et al.
Revue Des Maladies Respiratoires|February 3, 2007
The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancerR Rosell, T Moran, M Fernanda Salazar, et al.
Pageof 27

Showing results (201-210 of 265) with videos related to

Sort By:
Pageof 27
Oncogene|January 7, 1998
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosisJ M de Anta, E Jassem, R Rosell, et al.
Psychopharmacology|May 1, 2014
Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112Judy L Thompson, Daniel R Rosell, Mark Slifstein, et al.
Schizophrenia Research|April 12, 2024
The MATRICS consensus cognitive battery for the assessment of cognitive impairment in schizotypal personality disorderKatelyn N Challman, Daniel R Rosell, Deanna Barch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancerD Isla, R Rosell, J J Sánchez, et al.
The American Journal of Psychiatry|January 19, 2019
Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality DisorderMargaret M McClure, Fiona Graff, Joseph Triebwasser, et al.
British Journal of Cancer|March 26, 2008
ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimenJ Wei, Z Zou, X Qian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1997
Microsatellite alterations at 5q21, 11p13, and 11p15.5 do not predict survival in non-small cell lung cancerM Sánchez-Céspedes, R Rosell, A Pifarré, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2000
Altered HOX and WNT7A expression in human lung cancerR Calvo, J West, W Franklin, et al.
British Journal of Cancer|May 10, 2014
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancerJ Wei, C Costa, J Shen, et al.
Revue Des Maladies Respiratoires|February 3, 2007
The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancerR Rosell, T Moran, M Fernanda Salazar, et al.
Pageof 27